Press release
Thyroid Cancer Pipeline Report 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA
Explore our latest breakthroughs in Thyroid Cancer Research. Learn more about our innovative pipeline today! @ Thyroid Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Thyroid Cancer Pipeline Report
* June 2024:- Memorial Sloan Kettering Cancer Center- Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients. The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer.
* June 2024:- Dana-Farber Cancer Institute- A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer.This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for thyroid cancer.
* DelveInsight's Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
* The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
* Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
Stay informed about the cutting-edge advancements in Thyroid Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Thyroid Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer Emerging Drugs
* rhTSH: Suzhou Zelgen Biopharmaceuticals
Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.
* Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.
* RX208: Suzhou NeuPharma
RX208 is a potential "best-in-class" BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.
* AIC100: AffyImmune Therapeutics
AffyImmune's lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100's CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.
Learn more about Thyroid Cancer Drugs opportunities in our groundbreaking Thyroid Cancer Research and development projects @ Thyroid Cancer Unmet Needs [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Thyroid Cancer Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Thyroid Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer Drugs and Companies
* Rosiglitazone: Exelixis
* Lenvatinib: Eisai Limited
* Ifosfamide: Merck Sharp & Dohme LLC
Scope of the Thyroid Cancer Pipeline Report
* Coverage- 7MM
* Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
* Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
* Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Thyroid Cancer Pipeline on our website @ Thyroid Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Thyroid Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Thyroid Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* rhTSH: Suzhou Zelgen Biopharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Nivolumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AIC100:Affyimmune Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Thyroid Cancer Key Companies
* Thyroid Cancer Key Products
* Thyroid Cancer- Unmet Needs
* Thyroid Cancer- Market Drivers and Barriers
* Thyroid Cancer- Future Perspectives and Conclusion
* Thyroid Cancer Analyst Views
* Thyroid Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=thyroid-cancer-pipeline-report-2024-fda-approvals-clinical-trials-therapies-moa-roa]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Pipeline Report 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA here
News-ID: 3545420 • Views: …
More Releases from ABNewswire
Market Outlook Projects Steady Growth for Luxury Custom Home Builders in 2025
As families invest in properties that reflect their lifestyle and long-term goals, the role of custom home builders in Gulf Shores AL grows increasingly vital.
The demand for luxury custom home builders [https://ddandbllc.com/custom-home-pool-builder-gulf-shores-al/] continues to rise across the United States, with Gulf Shores, AL, emerging as a key market for homeowners seeking elegance, comfort, and modern design. While many search for home builders near me, the region shows strong momentum fueled…
Desman Orthodontics Launches "Smiles for Students" Scholarship Orthodonist Servi …
For many families in the area, finding a trusted local provider is a priority. As an established orthodontist Port St Lucie families have relied on for years, Desman Orthodontics is uniquely positioned to understand the needs of the community. The practice's decision to create this scholarship stems from a recognition that a healthy, confident smile can have a profound impact on a young person's social development and self-esteem, yet it…
Lone Wolf Roofing Strengthens Its Presence in LaPlace As the Top Roofer in LaPla …
Lone Wolf Roofing is the best roofer in LaPlace Louisiana.
Image: https://www.abnewswire.com/upload/2025/09/d18162e78e8b91dcdbe94df43778e8d2.jpg
Lone Wolf Roofing, a premier Louisiana-based roofing company, today announced the expansion of its services in LaPlace, offering homeowners and businesses access to unmatched craftsmanship, a 100-Year Warranty, and an unprecedented promise: if installation does not begin within 24 hours of signing, the roof is free.
With Louisiana communities facing recurring storms, unpredictable weather, and high roofing costs, Lone Wolf Roofing's…
Family-Owned Meigel Home Innovations Expands Operations to Meet Growing Kitchen …
The decision to expand was driven by a consistent increase in project inquiries over the past several years. "We've seen a fundamental shift," explains a company representative for Meigel Home Improvements. "Homeowners are no longer just fixing a leaky faucet or replacing worn-out countertops. They are undertaking comprehensive transformations. They want a kitchen remodel near me that reflects a modern lifestyle-open-concept layouts, smart storage solutions, and energy-efficient appliances.
HAUPPAUGE, NY -…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
